

Stabilis



Aldesleukin



Tradename

Interleukina Proleukin	Chile Belgium, Canada, Colombia, Denmark, Finland, France, Germany, Great Britain, Greece, Ireland, Italy, Luxembourg, Mexico, Netherlands, Spain, Switzerland, United Arab Emirates, United States of America, Venezuela
---------------------------	---



Stability in solutions

		18 MUI/ml	2-8°C		48			3635
		18 MUI/ml	30°C		48			3635



Factors which affect stability

				3635
				3635



Compatibility

	Aldesleukin : 0.0338 MUI/ml Amphotericin B : 1.6 mg/ml	
	Aldesleukin : 0.0338 MUI/ml Calcium gluconate : 100 mg/ml	
	Aldesleukin : 0.0338 MUI/ml Co-trimoxazole	
	Aldesleukin : 0.0338 MUI/ml Diphenhydramine hydrochloride : 50 mg/ml	
		Aldesleukin
	Aldesleukin : 0.0338 MUI/ml Dopamine hydrochloride : 1.6 mg/ml	
		3635
		36

		Aldesleukin : 0.0338 MUI/ml Fluconazole : 2 mg/ml		36
		Aldesleukin : 0.0338 MUI/ml Foscarnet sodium : 24 mg/ml		36
		Aldesleukin : 0.0338 MUI/ml Ganciclovir sodium : 10 mg/ml		36
		Aldesleukin : 0.0338 MUI/ml Heparin sodium : 100 UI/ml		36
		Aldesleukin : 0.0338 MUI/ml Lorazepam : 2 mg/ml		36
		Aldesleukin : 0.0338 MUI/ml Magnesium sulfate : 20 mg/ml		36
		Aldesleukin : 0.0338 MUI/ml Metoclopramide hydrochloride : 5 mg/ml		36
		Aldesleukin : 0.0338 MUI/ml Ondansetron hydrochloride : 0.7 mg/ml		36
		Aldesleukin : 0.0338 MUI/ml Pentamidine isetionate : 6 mg/ml		36
		Aldesleukin : 0.0338 MUI/ml Potassium chloride : 200 mEq/l		36
		Aldesleukin : 0.0338 MUI/ml Prochlorperazine edysilate : 5 mg/ml		36
		Aldesleukin : 0.0338 MUI/ml Promethazine hydrochloride : 25 mg/ml		36
		Aldesleukin : 0.0338 MUI/ml Ranitidine hydrochloride : 1 mg/ml		36
		Aldesleukin		3635



Route of administration











































References

	Type	Publication
36	Journal	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
3635	Manufacturer	Aldesleukine (Proleukin®) - Summary of Product Characteristics Novartis Pharmaceuticals UK Ltd 2015



Dictionary

 Anticancer drug	 Injection
 Tradename	 Stability in solutions
 Container	 Molecule
 Concentration	 Temperature
 Storage	 Duration of stability
 Biosimilar	 Conflicting data
 References	 Glass
 Water for Injection	 Protect from light
 Hour	 Not specified
 Factors which affect stability	 Filtration
 Induces	 Reduced stability
 Solvent	 Sodium chloride 0,9%
 Degradation	 Compatibility
 Compound	 Compatible
 Glucose 5%	 Unspecified incompatibility
 Incompatible	 Chemical instability
 Immediate precipitation	 Water for injection + antibacterial
 Route of administration	 Intravenous infusion
 Continuous infusion	 Subcutaneous
 References	 Dictionary